Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Can Fite BiopharmaCANF -3.37%52 Forward Rate of Return (Yacktman) % is 0.00% as of Dec. 2025. GuruFocus rates CANF with a GF Score™ of 52/100 and a GF Value™ of $6.01 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 180 Biotechnology companies, Can Fite Biopharma ranks worse than 555555% on this metric.
Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Can Fite Biopharma's forward rate of return for was 0.00%.
The historical rank and industry rank for Can Fite Biopharma's Forward Rate of Return (Yacktman) % or its related term are showing as below:
During the past 13 years, Can Fite Biopharma's highest Forward Rate of Return was 20.00. The lowest was 12.32. And the median was 20.00.
CANF's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 1.205 * Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Can Fite Biopharma (AMEX:CANF) Forward Rate of Return (Yacktman) % Explanation
Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.
Be Aware
In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.
Can Fite Biopharma Forward Rate of Return (Yacktman) % Related Terms
Can Fite Biopharma Forward Rate of Return (Yacktman) % Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's Forward Rate of Return (Yacktman) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma Forward Rate of Return (Yacktman) % Chart
CANF vs VRTX, REGN, RVMD: Forward Rate of Return (Yacktman) % Comparison
For the Biotechnology subindustry, Can Fite Biopharma's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma Forward Rate of Return (Yacktman) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Forward Rate of Return (Yacktman) % distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's Forward Rate of Return (Yacktman) % falls into.
Can Fite Biopharma Forward Rate of Return (Yacktman) % Calculation
Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Rate of Return (Yacktman) % of 0.00% mean?
Can Fite Biopharma (CANF) has a Forward Rate of Return (Yacktman) % of 0.00% as of Dec. 2025. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Can Fite Biopharma and its competitors. Over the past decade, Can Fite Biopharma's Forward Rate of Return (Yacktman) % has ranged from 12.32 to 20.00. According to the industry distribution chart, Can Fite Biopharma ranks #999999 out of 180 companies in the Biotechnology industry.
Is Can Fite Biopharma's Forward Rate of Return (Yacktman) % too high?
Can Fite Biopharma's current Forward Rate of Return (Yacktman) % is 0.00%. Over the past 10 years, this metric has ranged from a low of 12.32 to a high of 20.00. Based on the distribution chart, Can Fite Biopharma ranks #999999 out of 180 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Forward Rate of Return (Yacktman) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #999999 out of 180 companies for Forward Rate of Return (Yacktman) %. This places Can Fite Biopharma in the lower half of its industry. The industry median Forward Rate of Return (Yacktman) % is 1.21. Historically, Can Fite Biopharma's own Forward Rate of Return (Yacktman) % has ranged from 12.32 to 20.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Biotechnology company?
The median Forward Rate of Return (Yacktman) % among Biotechnology companies is 1.21, based on 180 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Can Fite Biopharma and its competitors. For the Biotechnology industry, the median Forward Rate of Return (Yacktman) % is 1.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current Forward Rate of Return (Yacktman) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.01, compared to a current price of $3.44 — trading 42.8% below its estimated fair value. The current Forward Rate of Return (Yacktman) % is 0.00%. Can Fite Biopharma's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Forward Rate of Return (Yacktman) % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $3.44 is trading 42.8% below its estimated GF Value™ of $6.01.
GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.
Key valuation signals for CANF:
Forward Rate of Return (Yacktman) %: 0.00%
GF Value™: $6.01 vs. price of $3.44 (42.8% below fair value)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
52GF Score
Get the complete analysis for CANF
Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
